v3.26.3
Income Taxes
 12 Months Ended
Jun. 30, 2026
Income Taxes [Abstract]  
INCOME TAXES
9. INCOME TAXES

 

Advanced Biomed Inc. is incorporated in the State of Nevada and is subject to U.S. federal income tax at a statutory rate of 21%. Nevada does not impose a state corporate income tax.

 

Acellent Technologies (Hong Kong) Co. Limited, which was acquired during the year ended June 30, 2026, is subject to Hong Kong profits tax. Under Hong Kong’s two-tiered profits tax regime, the first HK$2 million of a corporation’s assessable profits is taxed at 8.25%, and assessable profits in excess of HK$2 million are taxed at 16.5%.

 

For the year ended June 30, 2026, the Company recognized a deferred income tax benefit of $1,205 from continuing operations related to the recognition of a deferred tax asset for tax loss carryforwards of Acellent. The related deferred tax asset was $1,204 as of June 30, 2026.

 

The components of income tax benefit from continuing operations were as follows:

 

    For the years ended
June 30		  
    2026     2025  
    US$     US$  
Current income tax expense     —       —  
Deferred income tax benefit - Hong Kong income tax     (1,205 )     —  
Total income tax benefit from continuing operations     (1,205 )     —  

 

The following table reconciles income tax benefit computed at the U.S. federal statutory tax rate to income tax benefit from continuing operations:

 

    For the years ended
June 30		  
    2026     2025  
    %     %  
Tax at U.S. federal statutory rate     21.00       21.00  
State and local income taxes, net of federal effect     —       —  
Foreign tax effects     (0.03 )     —  
Changes in valuation allowance     (13.46 )     (21.00 )
Nondeductible expenses     (7.49 )     —  
Effective tax rate     0.02       0.00  

 

The components of deferred tax assets were as follows:

 

    As of
June 30,
2026		     As of
June 30,
2025		  
    US$     US$  
Net operating loss carryforwards     725,157       494,013  
Allowance for expected credit losses     612,971       —  
Gross deferred tax assets     1,338,128       494,013  
Less: valuation allowance     (1,336,924 )     (494,013 )
Deferred tax assets, net     1,204       —  

 

The Company recognized a deferred income tax benefit of $1,205 for the year ended June 30, 2026 related to a tax loss carryforward of Acellent. The corresponding deferred tax asset balance was $1,204 as of June 30, 2026. The difference between the benefit recognized during the year and the year-end asset reflects foreign currency translation. The Company’s U.S. deferred tax assets were fully offset by a valuation allowance as of June 30, 2026 and 2025. The net operating loss carry forwards for U.S. federal tax and Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable income. The U.S. federal net operating loss carry forward offset is limited to up to 80% of the taxable income.

 

For continuing operations, as of June 30, 2026 and 2025, the Company had total net operating loss carry forwards of approximately $3,561,863 and $2,352,444, respectively, which consists of Hong Kong net operating losses of $14,597 and nil, respectively and US net operating loss carry forwards of $3,447,396 and $2,352,444, respectively.

 

For discontinued operations, as of June 30, 2026 and 2025, the Company had total net operating loss carry forwards of approximately nil and $10,815,272, respectively, which consists of Taiwan net operating loss carry forwards nil and $5,824,336, China net operating loss carry forwards of nil and $4,896,250 and Hong Kong net operating loss carry forwards of nil and $94,686, respectively.